Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 35 for your search:
Start Over
Alternate Dosing Schedules Study for HPV Vaccine
Phase: Phase IV
Type: Prevention
Status: Completed
Age: 9 to 15
Sponsor: Other
Protocol IDs: Pro00014388, CDC#U36/CCU319276 CFDA 93.283, NCT00862810
Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India
Phase: Phase IV
Type: Prevention
Status: Closed
Age: 10 to 18
Sponsor: Other
Protocol IDs: BMGF48979, ISRCTN98283094, REFCTRI-2009 000137, NCT00923702
Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 13 to 15 at first immunization
Sponsor: Other
Protocol IDs: HPV CSP01, NCT00956553
Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease
Phase: Phase IV
Type: Prevention
Status: Completed
Age: 9 to 26
Sponsor: Other
Protocol IDs: 09-000485, NCT01034358
Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls
Phase: Phase IV
Type: Health services research, Natural history/Epidemiology, Prevention
Status: Completed
Age: 9 and over
Sponsor: Other
Protocol IDs: MITU-001, NCT01173900
V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)
Phase: Phase IV
Type: Prevention
Status: Closed
Age: 16 to 26
Sponsor: Pharmaceutical / Industry
Protocol IDs: V501-110, 132247, NCT01544478
A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501) in Women (V501-019)
Phase: Phase III
Type: Prevention
Status: Closed
Age: 24 to 45
Sponsor: Pharmaceutical / Industry
Protocol IDs: V501-019, 2004_013, NCT00090220
Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)
Phase: Phase III
Type: Prevention
Status: Completed
Age: 11 to 17
Sponsor: Pharmaceutical / Industry
Protocol IDs: V501-025, 2005_092, NCT00325130
Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 11 to 17
Sponsor: Pharmaceutical / Industry
Protocol IDs: V501-024, 2005_093, NCT00337428
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 18 to 45
Sponsor: Pharmaceutical / Industry
Protocol IDs: 108933, NCT00423046
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 9 to 15
Sponsor: Pharmaceutical / Industry
Protocol IDs: V501-029, 2006_038, NCT00380367
An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 9 to 26
Sponsor: Pharmaceutical / Industry
Protocol IDs: V501-030, 2007_021, NCT00496626
A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 9 to 26
Sponsor: Other
Protocol IDs: H07-00928, NCT00501137
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
Phase: Phase III
Type: Prevention
Status: Closed
Age: 16 to 26
Sponsor: Pharmaceutical / Industry
Protocol IDs: V503-001, 2007_538, NCT00543543
Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination
Phase: Phase III
Type: Prevention
Status: Completed
Age: 12 to 26
Sponsor: Other
Protocol IDs: RCH CA27091, NCT00964210
GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)
Phase: Phase III
Type: Prevention
Status: Completed
Age: 9 to 26
Sponsor: Pharmaceutical / Industry
Protocol IDs: V501-046, NCT01245764
Effect of Vaccination in Patients With Recurrent Respiratory Papillomatosis
Phase: Phase III
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: UHKT-RLP/2011, 2011-002667-14, NCT01375868
Evaluating the Effectiveness of the Quadrivalent Human Papillomavirus (HPV) Vaccine at Preventing Anal HPV Infection in HIV-Infected Men and Women
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Closed
Age: 27 and over
Sponsor: NIAID
Protocol IDs: A5298, 11798, NCT01461096
Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)
Phase: Phase III
Type: Prevention
Status: Closed
Age: 16 to 26
Sponsor: Pharmaceutical / Industry
Protocol IDs: V501-122, 132237, NCT01862874
A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men
Phase: Phase III
Type: Prevention
Status: Closed
Age: 16 to 26
Sponsor: Pharmaceutical / Industry
Protocol IDs: GDS07C, 2013-003399-10, V503-020, NCT02114385
Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 16 to 23
Sponsor: Pharmaceutical / Industry
Protocol IDs: V502-001, 2005_086, NCT00260039
V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 9 to 17
Sponsor: Pharmaceutical / Industry
Protocol IDs: V501-028, 2006_052, NCT00411749
Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: AMC-052, CDR0000559149, U01CA121947, 052, NCT00513526
Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)
Phase: Phase II
Type: Prevention
Status: Completed
Age: 16 to 26
Sponsor: Pharmaceutical / Industry
Protocol IDs: V505-001, 2007_567, NCT00520598
A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)
Phase: Phase II
Type: Prevention
Status: Completed
Age: 16 to 26
Sponsor: Pharmaceutical / Industry
Protocol IDs: V504-001, 2007_566, NCT00551187
Start Over